Caribou Biosciences/$CRBU
1D1W1MYTD1Y5YMAX
Capital at risk
About Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
- Ticker
- $CRBU
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 97
- Headquarters
- Berkeley, United States
- Website
- cariboubio.com
CRBU Metrics
BasicAdvanced
$136M
-
-$1.08
2.28
-
Price and volume
Market cap
$136M
Beta
2.28
52-week high
$3.54
52-week low
$1.26
Average daily volume
1.1M
Financial strength
Current ratio
6.487
Quick ratio
6.357
Long term debt to equity
25.767
Total debt to equity
27.171
Profitability
EBITDA (TTM)
-104.609
Gross margin (TTM)
-735.61%
Net profit margin (TTM)
-1,030.42%
Operating margin (TTM)
-1,068.22%
Effective tax rate (TTM)
0.53%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-36.84%
Return on equity (TTM)
-78.27%
Valuation
Price to revenue (TTM)
12.172
Price to book
1.37
Price to tangible book (TTM)
1.37
Price to free cash flow (TTM)
-1.276
Free cash flow yield (TTM)
-78.39%
Free cash flow per share (TTM)
-0.996
Growth
Revenue change (TTM)
10.02%
Earnings per share change (TTM)
-39.89%
3-year revenue growth (CAGR)
-11.04%
3-year earnings per share growth (CAGR)
-16.08%
What the Analysts think about CRBU
Analyst ratings (Buy, Hold, Sell) for Caribou Biosciences stock.
Analyst projections of the future price of Caribou Biosciences stock.
CRBU Financial Performance
Revenues and expenses
CRBU Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing CRBU
AllUSDGBP
Fund name | Fund size | $CRBU weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.